📊 AMLX Key Takeaways
Is Amylyx Pharmaceuticals, Inc. (AMLX) a Good Investment?
Amylyx is in severe financial distress with zero revenue and -$37M quarterly operating cash burn despite a strong balance sheet. With $229.1M cash reserves, the company has approximately 18-24 months of runway at current burn rates, but faces imminent insolvency without revenue recovery or dramatic cost restructuring. The deterioration from prior periods signals fundamental business failure rather than temporary challenges.
Amylyx's fundamentals are weak because revenue has fallen to zero while the company remains deeply unprofitable, with a $144.74M net loss and negative free cash flow of $123.48M. The balance sheet is still strong, supported by $226.65M of cash, minimal liabilities, and no long-term debt, but that financial cushion is being consumed by ongoing operating losses. Until the company restores a credible revenue base or materially reduces cash burn, fundamentals remain unfavorable.
Why Buy Amylyx Pharmaceuticals, Inc. Stock? AMLX Key Strengths
- Strong cash position of $229.1M with minimal debt (Debt/Equity 0.00x) providing near-term survival runway
- Solid balance sheet with $273.2M stockholders equity and only $20.4M total liabilities
- Exceptional liquidity ratios (17.85x current ratio) providing flexibility to address operational challenges
- Very strong liquidity, with a 14.27x current ratio and $226.65M in cash
- Debt-free balance sheet with low total liabilities relative to equity
- Large equity base of $305.26M provides near-term financial flexibility
AMLX Stock Risks: Amylyx Pharmaceuticals, Inc. Investment Risks
- Complete revenue collapse to $0 (down 100% YoY) indicating loss of primary commercial activity or major product discontinuation
- Negative operating cash flow of -$36.9M quarterly with company burning through cash reserves unsustainably
- Operating losses of -$43.8M and negative profitability metrics (ROE -15.1%, ROA -14.1%) indicating value destruction
- Limited runway of approximately 18-24 months before cash depletion at current burn rate
- No visibility to path to profitability or return to revenue generation
- Revenue has collapsed to $0, indicating severe commercial and growth deterioration
- Sustained operating and free cash flow losses are eroding the cash runway
- Negative ROE and ROA show the company is currently destroying shareholder capital rather than generating returns
Key Metrics to Watch
- Quarterly revenue and gross profit recovery from current zero baseline
- Operating cash flow trend and monthly cash burn rate to assess runway accuracy
- Operating expense reduction, headcount changes, and restructuring initiatives
- Strategic alternatives including M&A activity, partnerships, or asset sales
- Quarterly operating cash burn relative to cash balance
- Evidence of revenue recovery or new product commercialization progress
Amylyx Pharmaceuticals, Inc. (AMLX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 17.85x current ratio provides a solid financial cushion.
AMLX Profit Margin, ROE & Profitability Analysis
AMLX vs Healthcare Sector: How Amylyx Pharmaceuticals, Inc. Compares
How Amylyx Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Amylyx Pharmaceuticals, Inc. Stock Overvalued? AMLX Valuation Analysis 2026
Based on fundamental analysis, Amylyx Pharmaceuticals, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Amylyx Pharmaceuticals, Inc. Balance Sheet: AMLX Debt, Cash & Liquidity
AMLX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Amylyx Pharmaceuticals, Inc.'s revenue has grown significantly by 293% over the 5-year period, indicating strong business expansion. The most recent EPS of $-4.43 indicates the company is currently unprofitable.
AMLX Revenue Growth, EPS Growth & YoY Performance
AMLX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$34.4M | $-0.37 |
| Q2 2025 | -$1.0M | -$35.9M | $-0.46 |
| Q1 2025 | N/A | -$35.9M | $-0.42 |
| Q3 2024 | $416.0K | $1.6M | $0.30 |
| Q2 2024 | -$1.0M | $1.6M | $0.31 |
| Q1 2024 | $71.4M | $1.6M | $0.02 |
| Q3 2023 | $345.0K | $1.6M | $0.30 |
| Q2 2023 | $98.2M | $1.6M | $0.31 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Amylyx Pharmaceuticals, Inc. Dividends, Buybacks & Capital Allocation
AMLX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Amylyx Pharmaceuticals, Inc. (CIK: 0001658551)
📋 Recent SEC Filings
❓ Frequently Asked Questions about AMLX
What is the AI rating for AMLX?
Amylyx Pharmaceuticals, Inc. (AMLX) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are AMLX's key strengths?
Claude: Strong cash position of $229.1M with minimal debt (Debt/Equity 0.00x) providing near-term survival runway. Solid balance sheet with $273.2M stockholders equity and only $20.4M total liabilities. ChatGPT: Very strong liquidity, with a 14.27x current ratio and $226.65M in cash. Debt-free balance sheet with low total liabilities relative to equity.
What are the risks of investing in AMLX?
Claude: Complete revenue collapse to $0 (down 100% YoY) indicating loss of primary commercial activity or major product discontinuation. Negative operating cash flow of -$36.9M quarterly with company burning through cash reserves unsustainably. ChatGPT: Revenue has collapsed to $0, indicating severe commercial and growth deterioration. Sustained operating and free cash flow losses are eroding the cash runway.
What is AMLX's revenue and growth?
Amylyx Pharmaceuticals, Inc. reported revenue of $0.0.
Does AMLX pay dividends?
Amylyx Pharmaceuticals, Inc. does not currently pay dividends.
Where can I find AMLX SEC filings?
Official SEC filings for Amylyx Pharmaceuticals, Inc. (CIK: 0001658551) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AMLX's EPS?
Amylyx Pharmaceuticals, Inc. has a diluted EPS of $-0.37.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is AMLX a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Amylyx Pharmaceuticals, Inc. has a SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is AMLX stock overvalued or undervalued?
Valuation metrics for AMLX: ROE of -15.1% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy AMLX stock in 2026?
Our dual AI analysis gives Amylyx Pharmaceuticals, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is AMLX's free cash flow?
Amylyx Pharmaceuticals, Inc.'s operating cash flow is $-36.9M, with capital expenditures of $138.0K.
How does AMLX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -15.1% (avg: 15%), current ratio 17.85 (avg: 2).